Bogdan Iorga, Ph.D.
Affiliations: | 1998-2002 | École Polytechnique, Palaiseau, Île-de-France, France | |
| 2002- | ICSN | CNRS, Paris, Île-de-France, France |
Area:
Computational chemistry, Drug design, BioinformaticsGoogle:
"Bogdan Iorga"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Philippe Savignac | grad student | 1998-2001 | École Polytechnique | |
| (Synthèse d'alpha-monohalogénophosphonates par halogénation électrophile) | ||||
| Jean-Marc Campagne | post-doc | 2002-2003 | CNRS | |
Children
Sign in to add trainee| Marie Varin | grad student | 2004-2007 | Université Paris-Sud 11 |
| François Martz | grad student | 2011-2014 | Université Paris-Sud 11 |
| Maria-Laura-Belén Dabos | grad student | 2015-2018 | Université Paris-Saclay |
| Agustín Zavala | grad student | 2015-2018 | Université Paris-Saclay |
| Eddy Elisée | grad student | 2016-2019 | Université Paris-Saclay |
| Guillaume Bernadat | post-doc | 2009-2010 | CNRS |
| Najette Amara | post-doc | 2011-2012 | CNRS |
| Georgiana Surpateanu | post-doc | 2009-2013 | CNRS |
| Claire Colas | post-doc | 2011-2013 | CNRS |
| Cheickna Cissé | post-doc | 2012-2013 | CNRS |
| Edithe Selwa | post-doc | 2013-2018 | CNRS |
| Nawel Mele | post-doc | 2018-2019 | CNRS |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Denakpo E, Naas T, Iorga BI. (2023) An updated patent review of metallo-β-lactamase inhibitors (2020-2023). Expert Opinion On Therapeutic Patents. 33: 523-538 |
| Gaillot S, Oueslati S, Vuillemenot JB, et al. (2023) Genomic characterization of an NDM-9-producing clinical isolate and role of Glu152Lys substitution in the enhanced cefiderocol hydrolysis of NDM-9. Frontiers in Microbiology. 14: 1253160 |
| Dabos L, Raczynska JE, Bogaerts P, et al. (2023) Structural and Biochemical Features of OXA-517: a Carbapenem and Expanded-Spectrum Cephalosporin Hydrolyzing OXA-48 Variant. Antimicrobial Agents and Chemotherapy. e0109522 |
| Dahdouh E, Allander L, Falgenhauer L, et al. (2022) Computational Modeling and Design of New Inhibitors of Carbapenemases: A Discussion from the EPIC Alliance Network. International Journal of Molecular Sciences. 23 |
| Muntean MM, Muntean AA, Guerin F, et al. (2022) Optimization of the rapid carbapenem inactivation method for use with AmpC hyperproducers-authors' response. The Journal of Antimicrobial Chemotherapy |
| Jousset AB, Oueslati S, Emeraud C, et al. (2021) KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate. Antimicrobial Agents and Chemotherapy. 65: e0116021 |
| de Barsy M, Mercuri PS, Oueslati S, et al. (2021) Detection and characterization of VIM-52, a new variant of VIM-1 from clinical isolate. Antimicrobial Agents and Chemotherapy. AAC0266020 |
| Muntean MM, Muntean AA, Guerin F, et al. (2021) Optimization of the rapid carbapenem inactivation method for use with AmpC hyperproducers. The Journal of Antimicrobial Chemotherapy |
| Rima M, Emeraud C, Bonnin RA, et al. (2021) Biochemical characterization of OXA-244, an emerging OXA-48 variant with reduced β-lactam hydrolytic activity. The Journal of Antimicrobial Chemotherapy |
| Romero E, Oueslati S, Benchekroun M, et al. (2021) Azetidinimines as a novel series of non-covalent broad-spectrum inhibitors of β-lactamases with submicromolar activities against carbapenemases KPC-2 (class A), NDM-1 (class B) and OXA-48 (class D). European Journal of Medicinal Chemistry. 219: 113418 |